Insulin glargine as a second-line treatment after metformin in patients with type 2 diabetes is superior to adding the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin to achieve glycemic control, according to a first randomized head-to-head comparison of a DPP-4 and basal insulin presented at...
We investigated if metformin could be used to attenuate insulin secretion from palmitate-treated isolated islets and its implication for children with obesity. Human islets were exposed to palmitate for 0.5 or 1 day, when metformin was introduced. After culture, glucose-stimulated insulin secretion (...